Trial Profile

A Phase 1 trial of ABV-1601 for the treatment of Major depressive disorder in patients with cancers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PDC 1421 (Primary)
Indications Major depressive disorder
Focus Adverse reactions

Most Recent Events

14 Nov 2024 According to ABVC BioPharma media release, study is set to initiate by the end of 2024.
21 Mar 2024 New trial record
14 Mar 2024 According to ABVC BioPharma media release, ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate in Q2 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com